Tim Lowinger
Company: Mersana Therapeutics
Job title: Chief Scientific & Technology Officer
Seminars:
Chairperson’s Opening Remarks 8:25 am
day: day 2- am
Beyond Cytotoxic ADCs & Immunogenic Cell Death: Advancing ADCs Fully Into Immuno-oncology 4:45 pm
Design and optimization of the Immunosynthen STING agonist ADC platform Extensive characterization of the pre-clinical profile of XMT-2056, a novel, Her-2 targeted Immunosynthen ADC Translational Research demonstrating the mechanism of an Immnosynthen ADC and its ability to activate the STING pathway in tumor cells and tumor-resident immune cells to deliver a “1-2 punch”Read more
day: day 1- pm
Industry Leaders’ Panel Discussion 8:15 am
Outlining the most exciting developments within the last 12 months Exploring what the current clinical and commercialization landscape looks like Sharing the biggest up and coming trends within the ADC field Examining the next big challenges ADC developers will faceRead more
day: day 1- am